Nisa Investment Advisors LLC Increases Holdings in Hologic, Inc. (NASDAQ:HOLX)

Nisa Investment Advisors LLC increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 8.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 47,486 shares of the medical equipment provider’s stock after buying an additional 3,889 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Hologic were worth $3,393,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Hologic by 5.1% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider’s stock valued at $2,569,000 after purchasing an additional 1,631 shares during the period. LSV Asset Management raised its position in Hologic by 307.5% in the first quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider’s stock valued at $2,911,000 after purchasing an additional 28,600 shares during the period. Raymond James Trust N.A. raised its position in Hologic by 7.4% in the first quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider’s stock valued at $528,000 after purchasing an additional 476 shares during the period. Dimensional Fund Advisors LP raised its position in Hologic by 4.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock valued at $177,098,000 after purchasing an additional 106,315 shares during the period. Finally, Aviva PLC raised its position in Hologic by 0.7% in the first quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider’s stock valued at $5,803,000 after purchasing an additional 513 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Transactions at Hologic

In other news, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the sale, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at $7,793,700. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,846 shares of company stock valued at $2,473,443. 1.75% of the stock is currently owned by corporate insiders.

Hologic Trading Down 0.6 %

NASDAQ:HOLX opened at $77.33 on Friday. The stock has a 50-day simple moving average of $75.53 and a 200-day simple moving average of $72.33. The stock has a market cap of $18.15 billion, a P/E ratio of 36.65, a P/E/G ratio of 2.63 and a beta of 1.00. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $87.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.03. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.07 EPS. As a group, analysts anticipate that Hologic, Inc. will post 4.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

HOLX has been the topic of a number of research analyst reports. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and lifted their target price for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. StockNews.com downgraded Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Raymond James boosted their price objective on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Wednesday. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $87.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.